The review highlighted improvements with pioglitazone and lanifibranor (PPAR agonists), as well as with liraglutide and semaglutide (GLP-1R agonists), showing improvements in hepatic steatosis and lobular inflammation, and in some cases, resolution of NAFLD without exacerbating fibrosis [18]. This evidence concerns the gene GLP1R and fatty liver disease.